Sunshine Biopharma Inc Stock Price, News & Analysis

Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of Everolimus, a generic oncology drug, in the Canadian market through its subsidiary Nora Pharma Inc. Everolimus, a generic equivalent of Afinitor®, is designed to treat multiple conditions including advanced renal cell carcinoma, HER2-negative breast cancer, neuroendocrine tumors, and subependymal giant cell astrocytoma.

The drug is available in 2.5 mg, 5 mg, and 10 mg strengths in 30-tablet blister packs. The global Everolimus market, valued at $2.5 billion in 2023, is projected to reach $4.8 billion by 2032 with a 7.1% CAGR. The Canadian market segment represents approximately 2.2% of the global market and is growing at a 6.4% CAGR.

Sunshine Biopharma (NASDAQ:SBFM) has successfully closed its previously announced registered direct offering, raising approximately $2.46 million through the sale of Common Stock and pre-funded warrants to institutional investors. The offering, priced at $2.07 per share, included 1,188,404 shares of Common Stock or Pre-Funded Warrants.

The Pre-Funded Warrants, priced at $2.06999 with an exercise price of $0.00001, are immediately exercisable. The transaction, which closed on April 3, 2025, was conducted under Nasdaq rules at market price. The company plans to utilize the net proceeds for general corporate purposes and working capital.

Aegis Capital Corp. served as the exclusive placement agent, with legal representation from various firms. The offering was executed through an effective shelf registration statement on Form S-3.

Sunshine Biopharma (NASDAQ:SBFM) has announced a $2.46 million registered direct offering with institutional investors, priced at $2.07 per share of Common Stock under Nasdaq rules. The offering includes 1,188,404 shares of Common Stock or Pre-Funded Warrants, with the latter priced at $2.069 with a $0.001 exercise price.

The Pre-Funded Warrants will be immediately exercisable until fully exercised. The transaction is expected to close around April 3, 2025, subject to customary conditions. The company plans to use the proceeds for general corporate purposes and working capital. Aegis Capital Corp is serving as the exclusive placement agent.

The offering is being conducted through an effective shelf registration statement on Form S-3, previously declared effective by the SEC on January 15, 2025.

Sunshine Biopharma (NASDAQ:SBFM) has announced positive results from studies of its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) therapy for human hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths globally.

The company tested two versions of the treatment: a full-length mRNA (K1.1c) and a truncated version (K1.1d). Key findings include:

• The full-length K1.1c reduced growth of three different types of human HCC tumors in mice with good tolerability
• The truncated K1.1d showed significant anti-tumor activity in mouse HCC models in a dose-dependent manner
• Both versions were efficiently delivered to orthotopic engrafted HCC tumors through systemic administration

Additional animal studies are ongoing to determine optimal dosing of the truncated K1.1d version, which may offer better efficacy at lower doses compared to the full-length version.

Sunshine Biopharma (NASDAQ:SBFM) reported significant growth in fiscal 2024, with revenue reaching $34.9 million, marking a 45% increase from $24.1 million in 2023. Despite revenue growth, the company's net loss widened to $5.1 million from $4.5 million in 2023.

Key developments include:

• Completion of a $10 million public offering for sales operations expansion
• Launch of 13 new generic prescription drugs
• Health Canada approval for oncology drug NIOPEG®
• Publication of research on a new Coronavirus PLpro inhibitor
• Successful completion of mouse model studies for K1.1 mRNA Lipid Nanoparticle therapy for liver cancer treatment

The company's gross profit increased to $10.7 million, while general and administrative expenses rose to $16.5 million in 2024.

Sunshine Biopharma (NASDAQ:SBFM) has secured marketing rights for two new generic antibiotics in Canada through a strategic agreement. The company plans to launch these products through its subsidiary, Nora Pharma, within six to nine months pending regulatory approval.

The global antibiotics market, valued at $53.9 billion in 2024, is projected to reach $85.8 billion by 2033, growing at a CAGR of 5.3%. North America and Europe collectively hold approximately 45% market share, with Canada representing about 2.2% ($1.2 billion) of the global market.

These new antibiotics will complement Nora Pharma's existing portfolio of 70 generic prescription drugs currently marketed in Canada.

Sunshine Biopharma (NASDAQ:SBFM) has announced that its Canadian subsidiary, Nora Pharma, has acquired rights to two gastrointestinal drugs in the Canadian market, with one already launched and the second planned for launch within 9 months.

The first launched drug is Prucalopride, a generic version of Resotran®, available in 1mg and 2mg tablet strengths. The drug treats chronic idiopathic constipation in adult women when laxatives are ineffective by stimulating 5-HT4 receptors to enhance gastrointestinal motility.

Both drugs target the chronic idiopathic constipation submarket within Canada's $200 million CAD gastrointestinal market. The sector is projected to grow at a 4.64% CAGR from 2024 to 2034, driven by increasing gastrointestinal disorder prevalence and treatment awareness.